CoChat

MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase

Open access
Bayraktar, Recep, Pichler, Martin, Kanlikilicer, Pinar, Ivan, Cristina, Bayraktar, Emine, Kahraman, Nermin, Aslan, Burcu, Oguztuzun, Serpil, Ulasli, Mustafa, Arslan, Ahmet, Calin, George, Lopez-Berestein, Gabriel, Ozpolat, Bulent · 2017 · Oncotarget
Cited by 138

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

// Recep Bayraktar 1, 2 , Martin Pichler 4 , Pinar Kanlikilicer 1 , Cristina Ivan 1, 4 , Emine Bayraktar 1, 2 , Nermin Kahraman 1 , Burcu Aslan 1 , Serpil Oguztuzun 3 , Mustafa Ulasli 2 , Ahmet Arslan 2 , George Calin 1, 4 , Gabriel Lopez-Berestein 1, 4 , Bulent Ozpolat 1, 4 1 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Department of Medical Biology, School of Medicine, Gaziantep University, Gaziantep, Turkey 3 Department of Biology, Kirikkale University, Kirikkale, Turkey 4 Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence to: Bulent Ozpolat, email: Bozpolat@mdanderson.org. Keywords: eEF2K, triple negative breast cancer, liposomes, nanoparticles, miR-603 Received: June 29, 2016 Accepted: November 30, 2016 Published: December 27, 2016 ABSTRACT Triple negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by the absence of defined molecular targets, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and is associated with high rates of relapse and distant metastasis despite surgery and adjuvant chemotherapy. The lack of effective targeted therapies for TNBC represents an unmet therapeutic challenge. Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical calcium/calmodulin-dependent serine/threonine kinase that promotes TNBC tumorigenesis, progression, and drug resistance, representing a potential novel molecular target. However, the mechanisms regulating eEF2K expression are unknown. Here, we report that eEF2K protein expression is highly up-regulated in TNBC cells and patient tumors and it is associated with poor patient survival and clinical outcome. We found that loss/reduced expression of miR-603 leads to eEF2K overexpression in TNBC cell lines. Its expression results in inhibition of eEF2K by directly targeting the 3-UTR and the inhibition of tumor cell growth, migration and invasion in TNBC. In vivo therapeutic gene delivery of miR-603 into TNBC xenograft mouse models by systemic administration of miR-603-nanoparticles led to a significant inhibition of eEF2K expression and tumor growth, which was associated with decreased activity of the downstream targets of eEF2K, including Src, Akt, cyclin D1 and c-myc. Our findings suggest that miR-603 functions as a tumor suppressor and loss of miR-603 expression leads to increase in eEF2K expression and contributes to the growth, invasion, and progression of TNBC. Taken together, our data suggest that miR-603-based gene therapy is a potential strategy against TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.14264

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Bayraktar, R., Pichler, M., Kanlikilicer, P., Ivan, C., Bayraktar, E., Kahraman, N., Aslan, B., Oguztuzun, S., Ulasli, M., Arslan, A., Calin, G., Lopez-Berestein, G., & Ozpolat, B.
Venue
Oncotarget
Published
2016-12-27
Volume
8
Issue
7
Pages
11641-11658
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2567652734
Cited by
138
References
2
FWCI
2.43
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.